Osteopontin and Mesothelioma: What Research Says About This Potential Biomarker

Osteopontin has attracted scientific interest as a potential biomarker for malignant pleural mesothelioma, particularly because elevated levels have been observed in the blood of some patients with the disease.

Interest increased substantially after a 2005 study reported that serum osteopontin levels could distinguish patients with pleural mesothelioma from people with asbestos exposure who did not have cancer. The findings raised an important possibility: Could a blood-based marker help identify mesothelioma earlier?

Research since then has provided a more complicated answer.

Osteopontin remains scientifically relevant to mesothelioma research, but current evidence does not support using an osteopontin blood test alone to screen for, confirm, or rule out mesothelioma. Its levels can be affected by other cancers and noncancerous inflammatory or fibrotic conditions, and studies have reported variable diagnostic performance.

Understanding that distinction is essential. A promising biomarker can contribute valuable information to research without being accurate enough to function as a standalone clinical test.

What Is Osteopontin?

Osteopontin is a phosphorylated glycoprotein encoded by the SPP1 gene. It is found in several tissues and body fluids and participates in a range of biological processes, including immune regulation, inflammation, cell adhesion, tissue remodeling, and cell migration.

The protein was initially studied extensively in relation to bone biology, which is reflected in its name. However, researchers later found that osteopontin has much broader biological functions.

Osteopontin expression can increase in various disease states. Elevated levels or altered expression have been investigated in connection with inflammatory disorders, tissue fibrosis, and several cancers.

This broad biological activity is important when evaluating osteopontin as a cancer biomarker. A marker that rises in several unrelated conditions may have difficulty distinguishing one specific cancer from other diseases.

Why Have Researchers Studied Osteopontin in Mesothelioma?

Malignant pleural mesothelioma is strongly associated with asbestos exposure and can develop decades after the relevant exposure occurred.

This long latency period creates an important research challenge. Scientists have investigated whether measurable biological changes could help identify disease before symptoms and extensive tumor growth make the cancer clinically apparent.

A useful blood biomarker for early detection would ideally distinguish:

• people with asbestos exposure who remain cancer-free;
• people with benign asbestos-related disease;
• patients with early mesothelioma;
• patients with other cancers; and
• people with inflammatory or fibrotic diseases that can produce similar biological changes.

Osteopontin became a candidate partly because research identified increased expression in mesothelioma tissue and elevated circulating levels in patients with malignant pleural mesothelioma.

The key question, however, is not simply whether osteopontin levels can be elevated in mesothelioma. For a biomarker to become clinically useful for screening or diagnosis, researchers need to determine how reliably it identifies the disease while avoiding excessive false-positive and false-negative results.

The 2005 Study That Increased Interest in Osteopontin

A major point in osteopontin research came in 2005, when researchers led by Harvey I. Pass and colleagues published a study in The New England Journal of Medicine examining asbestos exposure, pleural mesothelioma, and serum osteopontin levels.

The study included 190 participants divided into three groups:

• 69 participants with nonmalignant asbestos-related disease;
• 45 current smokers without known asbestos exposure; and
• 76 patients with pleural mesothelioma.

Researchers found that mean serum osteopontin levels were substantially higher among patients with pleural mesothelioma than among participants with asbestos exposure who did not have cancer.

At one reported cutoff, the study found a sensitivity of 77.6% and specificity of 85.5% when comparing the mesothelioma group with the asbestos-exposed group.

In a subgroup comparison involving stage I mesothelioma, the reported sensitivity was 84.6% and specificity was 88.4% at a different cutoff.

These findings generated considerable interest because identifying mesothelioma at an earlier stage has long been a major research goal.

However, the findings did not establish an osteopontin blood test as a definitive diagnostic or population screening test. They provided evidence that justified further validation.

Understanding Sensitivity and Specificity

Sensitivity and specificity are important when evaluating a potential diagnostic biomarker.

Sensitivity describes how often a test correctly identifies people who have the disease. A test with imperfect sensitivity can produce false-negative results, meaning some people with the disease may receive a negative result.

Specificity describes how often a test correctly identifies people who do not have the disease. A test with imperfect specificity can produce false-positive results, meaning some people without the cancer may have an elevated result.

These issues become particularly important when considering screening for a rare cancer.

Even a biomarker that performs reasonably well in a selected research population may generate problematic numbers of false-positive results when applied broadly. This is one reason promising case-control study results require validation in appropriate prospective populations before a biomarker can be recommended for routine screening.

What Did Later Research Find?

Research following the initial osteopontin study produced a more nuanced picture.

A systematic review and meta-analysis evaluating circulating osteopontin for malignant pleural mesothelioma reported pooled diagnostic sensitivity of approximately 65% and specificity of approximately 81%.

Those figures suggest that osteopontin contains diagnostic information, but they also illustrate significant limitations if the marker is used alone.

At a sensitivity of 65%, a substantial proportion of people with mesothelioma could potentially be missed. At a specificity of 81%, some people without mesothelioma could receive positive results.

Researchers have also identified variation between studies. Differences can arise from:

• the characteristics of the study population;
• the comparison or control groups used;
• sample size;
• assay methods;
• cutoff values;
• whether serum or plasma is tested;
• sample handling and storage;
• disease stage;
• histologic subtype; and
• the presence of other inflammatory, fibrotic, or malignant conditions.

These sources of variation help explain why a promising result from an initial study does not automatically translate into a reliable screening test.

Can an Osteopontin Blood Test Detect Mesothelioma Early?

Current evidence does not support using an osteopontin blood test by itself to detect early mesothelioma in routine clinical practice.

The original study generated interest because elevated levels were observed even among patients with early-stage disease. However, demonstrating a difference between groups in a research study is not the same as proving that a test improves early detection in real-world screening.

For an early-detection biomarker to become clinically useful, researchers generally need evidence that it performs reliably in the population where it will be used.

For mesothelioma, this is particularly challenging because people with historical asbestos exposure may also have benign pleural abnormalities, fibrosis, chronic inflammation, or other medical conditions.

Osteopontin levels can be influenced by biological processes beyond mesothelioma, limiting the specificity of the marker.

Therefore, an elevated osteopontin level cannot establish that a person has mesothelioma, while a low level cannot reliably exclude the disease.

Why Is Osteopontin Not a Standalone Diagnostic Test?

Several limitations prevent osteopontin from functioning as a standalone diagnostic test for mesothelioma.

1. Osteopontin Is Not Specific to Mesothelioma

Osteopontin is involved in inflammation, immune responses, fibrosis, tissue remodeling, and cancer biology.

Its expression or circulating levels can be altered in conditions other than mesothelioma. Researchers have investigated osteopontin in several cancers and in nonmalignant inflammatory and fibrotic diseases.

A biomarker that responds to multiple biological processes may help provide information but may lack the specificity required to identify one particular disease.

2. Study Results Have Varied

The diagnostic performance reported for osteopontin has not been identical across studies.

Differences in study design, participant selection, laboratory methods, sample type, and cutoff values can affect estimates of sensitivity and specificity.

This heterogeneity complicates the development of a standardized clinical threshold.

3. Serum and Plasma Measurements Require Careful Interpretation

Osteopontin can be measured in serum or plasma, but pre-analytical and analytical factors can affect biomarker research.

The type of sample, collection procedures, storage, processing, and assay methodology can influence measured concentrations and comparability between studies.

Standardization is important before a biomarker can move from research into routine clinical use.

4. A Blood Marker Does Not Replace Tissue Diagnosis

Mesothelioma diagnosis generally requires integration of clinical history, imaging, pathology, and other relevant findings.

A biomarker result cannot determine the complete histologic and molecular characteristics of a tumor. Tissue examination remains central to distinguishing mesothelioma from other malignancies that can involve the pleura.

This distinction is particularly important because metastatic cancers can spread to the pleura and may resemble mesothelioma clinically or radiographically.

What Happens When Mesothelioma Is Suspected?

When mesothelioma is suspected, clinicians evaluate the entire clinical picture rather than relying on a single blood marker.

The process may include:

• detailed medical and occupational history;
• assessment of possible asbestos exposure;
• physical examination;
• chest imaging;
• CT scanning;
• PET or MRI in selected clinical situations;
• evaluation of pleural fluid when present; and
• biopsy for pathological examination when appropriate.

Pathologists may use microscopic features and immunohistochemical markers to distinguish mesothelioma from other cancers.

This diagnostic pathway is different from measuring a circulating biomarker. Biomarkers may have potential roles as complementary tools, but they should not be confused with definitive pathological diagnosis.

Osteopontin Compared With Other Mesothelioma Biomarkers

Osteopontin is one of several biomarkers that researchers have investigated in mesothelioma.

Other research targets have included:

• soluble mesothelin-related peptides;
• megakaryocyte potentiating factor;
• fibulin-3;
• high-mobility group box 1, or HMGB1;
• microRNAs;
• circulating tumor-related material; and
• multi-marker or molecular signatures.

Each approach has potential strengths and limitations.

A single biomarker may perform differently according to disease stage, histologic subtype, patient characteristics, and the biological question being asked. For this reason, researchers have also explored whether combinations of biomarkers or multimodal approaches could perform better than relying on one marker.

This broader field remains an active area of investigation. Evidence supporting one biomarker should not automatically be generalized to another because each marker requires independent validation for a specific clinical use.

Osteopontin and MESOMARK Are Not the Same Test

For U.S. readers, it is important to distinguish osteopontin research from the MESOMARK assay.

MESOMARK measures soluble mesothelin-related peptides, or SMRP. It does not measure osteopontin.

The U.S. Food and Drug Administration authorized MESOMARK under a Humanitarian Device Exemption as an aid in monitoring patients diagnosed with epithelioid or biphasic mesothelioma.

That indication is different from population screening or standalone diagnosis.

In other words, the existence of an authorized mesothelioma-related blood assay does not mean that all investigated mesothelioma biomarkers have equivalent clinical roles. It also does not mean that a blood test can replace imaging, biopsy, pathology, or specialist evaluation when mesothelioma is suspected.

Could Osteopontin Be Used as Part of a Biomarker Panel?

One direction in biomarker research is the use of combinations rather than a single marker.

This approach is biologically plausible because mesothelioma is a complex disease. Different biomarkers may reflect different aspects of tumor biology, inflammation, tissue injury, immune responses, or disease burden.

In principle, combining complementary signals could improve discrimination. However, a biomarker panel still requires rigorous validation.

Researchers need to determine:

• whether the combination performs better than individual markers;
• whether results are reproducible in independent populations;
• whether assays can be standardized;
• whether the panel works in early-stage disease;
• whether it distinguishes cancer from benign asbestos-related disease;
• whether it improves clinical decision-making; and
• whether its benefits outweigh potential harms and costs.

Promising research performance alone is not sufficient to establish a screening program.

Why Is Early Detection of Mesothelioma So Difficult?

Early detection is challenging for several reasons.

First, mesothelioma can develop many decades after asbestos exposure. People may no longer remember or recognize exposures that occurred during earlier employment, military service, building renovation, industrial work, or household contact.

Second, early symptoms can be nonspecific. Shortness of breath, chest discomfort, cough, and fatigue can occur in many more common medical conditions.

Third, mesothelioma is rare. Screening rare diseases requires particularly careful attention to false-positive results.

Fourth, asbestos-exposed populations are not biologically uniform. Differences in exposure intensity, duration, fiber type, age, smoking history, and coexisting asbestos-related disease can complicate risk assessment and biomarker interpretation.

These challenges explain the continuing scientific interest in blood biomarkers while also showing why evidence must be interpreted cautiously.

What Is the Current Role of Osteopontin in Mesothelioma?

The most accurate description is that osteopontin remains a potential and investigational biomarker in the context of mesothelioma.

Research has established several important observations:

• osteopontin expression can be elevated in mesothelioma;
• circulating levels have differed between mesothelioma cases and comparison groups in multiple studies;
• the original 2005 study reported promising diagnostic discrimination;
• pooled evidence has shown more modest diagnostic performance;
• osteopontin lacks sufficient disease specificity for standalone diagnosis;
• methodological and population differences affect study results; and
• further validation is needed to define any clinically useful role.

The evidence therefore supports continued research, but not claims that an osteopontin blood test can independently confirm early-stage mesothelioma.

What Should People With Past Asbestos Exposure Know?

A history of asbestos exposure does not mean that a person will develop mesothelioma. However, exposure history can be important medical information.

People concerned about previous exposure should provide healthcare professionals with as much detail as possible about:

• previous occupations;
• industries and job sites;
• military service;
• construction, demolition, or renovation work;
• shipyard or industrial employment;
• insulation work;
• household contact with someone who worked around asbestos; and
• possible environmental exposure.

People should not rely on experimental biomarker tests to diagnose themselves or rule out disease.

Persistent or unexplained symptoms such as shortness of breath, chest pain, ongoing cough, or other concerning changes should be medically evaluated. The appropriate evaluation depends on symptoms, exposure history, medical history, and other individual factors.

The Bottom Line

Osteopontin is a biologically important protein that has been studied as a potential biomarker for malignant pleural mesothelioma.

The influential 2005 study found substantially higher serum osteopontin levels among patients with pleural mesothelioma than among asbestos-exposed participants without cancer. Those results created legitimate scientific interest in the possibility of blood-based detection.

Later research, however, showed that the picture is more complex. Osteopontin can be elevated in other malignant and nonmalignant conditions, diagnostic performance has varied across studies, and pooled evidence indicates limitations in sensitivity and specificity.

For these reasons, an osteopontin blood test should not be presented as a standalone method for screening, confirming, or ruling out mesothelioma.

The molecule remains relevant to biomarker research, including studies of multi-marker strategies and other approaches to earlier detection. For patients with suspected mesothelioma, diagnosis continues to depend on appropriate clinical evaluation, imaging, and pathological examination rather than a single experimental blood marker.